KSM Research and Innovation Center and Valo Health Announce First-of-Its-Kind Multiyear Collaboration to Spearhead Preventative Care and Personalized Medicine for Patients

Collaboration to leverage KSM'S biobank - the largest in Israel and one of the most comprehensive globally

BOSTON, Sept. 19, 2022 /​PRNewswire/​— Kahn-Sagol-Mac­cabi (KSM), the research and inno­va­tion cen­ter of Israel’s lead­ing HMO — Mac­cabi Health­care Ser­vices, and Valo Health, Inc. (“Valo”), the tech­nol­o­gy com­pa­ny focused on trans­form­ing the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence, announced today a first-of-its-kind mul­ti­year col­lab­o­ra­tion in which Valo and Mac­cabi KSM Research and Inno­va­tion’s Biobank will joint­ly con­duct research lever­ag­ing Val­o’s Opal Com­pu­ta­tion­al Plat­form™ to iden­ti­fy pre­ven­tive care and per­son­al­ized med­i­cine for patients.

The col­lab­o­ra­tion between Valo and KSM’s Biobank, the largest in Israel and one of the most com­pre­hen­sive and rich­est data sets glob­al­ly, is expect­ed to lead to inno­v­a­tive stud­ies that ana­lyze com­plex dis­eases, iden­ti­fy con­nec­tions between dis­eases, pre­dict new sub­pop­u­la­tions with­in our cur­rent knowl­edge of dis­eases and gen­er­ate new insights about dis­ease treat­ment and pre­ven­tion using Val­o’s Opal Plat­form. KSM’s Biobank includes more than 800,000 de-iden­ti­fied bio­log­i­cal sam­ples of Mac­cabi mem­bers vol­un­teers who have agreed to join the Biobank project pro­mot­ing genet­ic research.

Valo is hon­ored to launch this unique col­lab­o­ra­tion with Mac­cabi KSM,” said Val­o’s founder and CEO David Berry. As a leader in ful­ly inte­grat­ing and lever­ag­ing patient data with AI-pow­ered com­pu­ta­tion­al capa­bil­i­ties, Valo is well-posi­tioned to gen­er­ate sig­nif­i­cant val­ue for Mac­cabi’s patients by iden­ti­fy­ing insights to help iden­ti­fy and treat com­plex dis­eases ear­li­er and sup­port bet­ter treat­ment decisions.”

This col­lab­o­ra­tion gives us the oppor­tu­ni­ty to con­nect genet­ic infor­ma­tion to a med­ical file and enable a research sequence that will gen­er­ate insights into human dis­ease, that is beyond what is known today,” said Dr. Tal Pat­alon, head of KSM. The goal is to cre­ate a leap for­ward in the fields of med­ical inno­va­tion and per­son­al­ized medicine.”

About Kahn-Sagol-Mac­cabi (KSM):
Kahn-Sagol-Mac­cabi (KSM) is the Research and Inno­va­tion Cen­ter of Mac­cabi Health­care Ser­vices, Israel’s lead­ing HMO. KSM has a unique access to Mac­cabi’s pro­fes­sion­al abil­i­ties and med­ical knowl­edge, includ­ing a large data­base of 2.5 mil­lion mem­bers with 30 years of data col­lec­tion. For more details, vis­it www​.ksmin​no​va​tion​.com.

About Valo Health:
Valo Health, Inc. (“Valo”) is a tech­nol­o­gy com­pa­ny built to trans­form the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence-dri­ven com­pu­ta­tion. As a dig­i­tal­ly native com­pa­ny, Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life cycle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing costs, time, and fail­ure rates. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form™ is an inte­grat­ed set of capa­bil­i­ties designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams across car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in San Fran­cis­co, CA, New York, NY, Lex­ing­ton, MA, and Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.